<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286960</url>
  </required_header>
  <id_info>
    <org_study_id>13-00096</org_study_id>
    <nct_id>NCT02286960</nct_id>
  </id_info>
  <brief_title>Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes</brief_title>
  <acronym>AAO</acronym>
  <official_title>Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the considerable use of oral steroids in the regular management of benign vocal fold
      lesions there is little evidence base in the literature. This study will investigate the
      efficacy of oral steroids for the treatment of vocal fold lesions in a controlled manner. The
      specific aim of this study is to determine the effectiveness of of a short course of oral
      steroids prior to behavioral voice therapy in patients with benign, phonotraumatic vocal fold
      lesions. Enrolled subjects will be randomized using a random numbers table to either receive
      oral steroids or no steroids prior to the initiation of voice therapy. The therapist and
      individuals involved in the collection and analysis of data will be blinded as to whether the
      subject received drug. Prior to initiation of therapy subjects will be asked to return for an
      interval evaluation during which they undergo videostroboscopy and voice evaluation. Subjects
      will enter then the voice therapy phase . After an initial evaluation to determine the best
      mode of therapy they will receive a behavioral voice therapy course, which includes a range
      of behavioral modifications and motor learning techniques, along with lifestyle measures. In
      all these phases acoustic and aerodynamic measurements will be collected as well as
      audio-visual material from the videostroboscopic exams. The investigators hypothesize that
      oral steroids will lead to a reduction in lesion size, which will substantially aid in the
      delivery and incorporation of voice therapy techniques, contributing to the improvement of
      overall laryngeal biomechanics and providing an ideal starting point for behavioral voice
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate the potential added advantage of the use of steroids in patients
      undergoing voice therapy. Enrolled subjects will be randomized using a random numbers table
      to either receive oral steroids or no steroids prior to the initiation of voice therapy. The
      therapist and individuals involved in the collection and analysis of data will be blinded as
      to whether the subject received drug. Prior to initiation of therapy subjects will be asked
      to return for an interval evaluation during which they undergo videostroboscopy and voice
      evaluation. Subjects will enter then the voice therapy phase . After an initial evaluation to
      determine the best mode of therapy they will receive a behavioral voice therapy course, which
      includes a range of behavioral modifications and motor learning techniques, along with
      lifestyle measures. In all these phases acoustic and aerodynamic measurements will be
      collected as well as audio-visual material from the videostroboscopic exams. The measurements
      that will be collected in all these phases are the Voice Handicap Index (VHI)-10 , the noise
      to harmonic ratio H/N, the fundamental frequency Fo, The transglottic airflow and subglottic
      pressure. The investigators hypothesize that oral steroids will lead to a reduction in lesion
      size, which will substantially aid in the delivery and incorporation of voice therapy
      techniques, contributing to the improvement of overall laryngeal biomechanics and providing
      an ideal starting point for behavioral voice therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score From Baseline to 2 Months</measure>
    <time_frame>pre-treatment/baseline to 2 months</time_frame>
    <description>Data will be collected via measurement of the hatchmark on the 100mm line for each variable (e.g. 72/100). The higher the score, the higher the deviancy. The final score is the average of scores from each variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lesion Size From Baseline to 2 Months</measure>
    <time_frame>pre-treatment/baseline to 2 months</time_frame>
    <description>Still images of the glottis will be obtained from the video such that the vocal folds are captured in an open position (at least 40 degrees at the anterior commissure). Image J software (NIH) will then be used to outline the lesion and measure the length of the ipsilateral vocal fold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Voice Handicap Index (VHI) Scores From Baseline to 2 Months.</measure>
    <time_frame>Pre-treatment/baseline to following treatment/2 months</time_frame>
    <description>A change in VHI scores from pre-treatment to following treatment.
Scores can range from 0-120:
0-30: Mild Minimal amount of handicap 31-60: Moderate Often seen in patients with vocal nodules, polyps, or cysts 60-120: Severe Often seen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Showed Improved (Lower) Average Decibels (db) Output.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Dysphonia</condition>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednizone pills. 4 day course 2 x 20mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose Pills. 4 day course 2 x 20mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid</intervention_name>
    <description>A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
    <arm_group_label>Steroid</arm_group_label>
    <other_name>Prednizone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose Pills</intervention_name>
    <description>4 day course 2 x 20mg per da</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 males and females

          -  Presence of phonotraumatic lesion deemed to be etiologic for the complaint of
             dysphonia

          -  Voice therapy deemed to be the primary (or at least initial) treatment to address the
             dysphonia.

          -  Willingness to be an active participant in voice therapy.

        Exclusion Criteria:

          -  Use of any glucocorticoids (oral, inhaled, or intravenous) within 3 months of the
             initial evaluation

          -  Known allergy or hypersensitivity to oral steroids

          -  Active infection

          -  Diabetes Mellitus

          -  Prior history of radiation to the neck

          -  Recent myocardial infarction

          -  Recent gastrointestinal surgery with bowel anastamosis (3 months)

          -  Active peptic ulcer

          -  Pregnancy

          -  Severe depression or history of psycosis

          -  History of recent laryngeal surgery (within 12 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Amin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>October 2, 2019</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysphonia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02286960/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Steroid</title>
          <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 6 patients were lost to follow up.</population>
      <group_list>
        <group group_id="B1">
          <title>Steroid</title>
          <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score From Baseline to 2 Months</title>
        <description>Data will be collected via measurement of the hatchmark on the 100mm line for each variable (e.g. 72/100). The higher the score, the higher the deviancy. The final score is the average of scores from each variable.</description>
        <time_frame>pre-treatment/baseline to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score From Baseline to 2 Months</title>
          <description>Data will be collected via measurement of the hatchmark on the 100mm line for each variable (e.g. 72/100). The higher the score, the higher the deviancy. The final score is the average of scores from each variable.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.21"/>
                    <measurement group_id="O2" value="0.65" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lesion Size From Baseline to 2 Months</title>
        <description>Still images of the glottis will be obtained from the video such that the vocal folds are captured in an open position (at least 40 degrees at the anterior commissure). Image J software (NIH) will then be used to outline the lesion and measure the length of the ipsilateral vocal fold.</description>
        <time_frame>pre-treatment/baseline to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lesion Size From Baseline to 2 Months</title>
          <description>Still images of the glottis will be obtained from the video such that the vocal folds are captured in an open position (at least 40 degrees at the anterior commissure). Image J software (NIH) will then be used to outline the lesion and measure the length of the ipsilateral vocal fold.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4694" spread="0.5494"/>
                    <measurement group_id="O2" value="0.2788" spread="0.3026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Voice Handicap Index (VHI) Scores From Baseline to 2 Months.</title>
        <description>A change in VHI scores from pre-treatment to following treatment.
Scores can range from 0-120:
0-30: Mild Minimal amount of handicap 31-60: Moderate Often seen in patients with vocal nodules, polyps, or cysts 60-120: Severe Often seen</description>
        <time_frame>Pre-treatment/baseline to following treatment/2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Voice Handicap Index (VHI) Scores From Baseline to 2 Months.</title>
          <description>A change in VHI scores from pre-treatment to following treatment.
Scores can range from 0-120:
0-30: Mild Minimal amount of handicap 31-60: Moderate Often seen in patients with vocal nodules, polyps, or cysts 60-120: Severe Often seen</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="-.2" upper_limit=".9"/>
                    <measurement group_id="O2" value="0.40" lower_limit=".15" upper_limit=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Showed Improved (Lower) Average Decibels (db) Output.</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Steroid</title>
            <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Showed Improved (Lower) Average Decibels (db) Output.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Steroid</title>
          <description>Prednizone pills. 4 day course 2 x 20mg per day.
Steroid: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Lactose Pills. 4 day course 2 x 20mg per day.
Lactose Pills: 4 day course 2 x 20mg per da</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Milan Amin</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>646-754-1206</phone>
      <email>Milan.Amin@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

